Mitsiades Lab
Principal Investigator: Constantine S. Mitsiades
Institution: Dana-Farber Cancer Institute (Boston, MA)
Primary Subfield: Molecular & Cell Bio
Recruitment Status: Inquire for rotation/fellowship opportunities
Research Focus
PROJECT SUMMARY Significance: Currently available pharmacological therapies for hematologic malignancies, including multiple myeloma (MM) and myeloid leukemias often fail, despite ongoing treatment, to eradicate all malignant cells, resulting in establishment of treatment-persistent residual disease TPRD (often referred to as “minimal” residual disease, MRD), which serves as a reservoir for eventual patient relapses. Despite the critical role of TPRD/MRD tumor cells as a barrier to cure, their biology and therapeutic vulnerabilities, including immune responsiveness, has remained understudied. Preliminary data: Our recent studies and preliminary data indicate that treatment- persistent cancer cells in acute myeloid leukemia (AML), MM, and solid tumors persist through cytotoxic drug treatments via a non-genetic (and reversible upon drug withdrawal) low-Myc tumor cell state with transcriptional changes resembling embryonic diapause, a stress-induced dormant stage of suspended development in many species. In parallel to these studies, our collaborating labs characterized, through CRISPR and pooled pheno- typic studies, the molecular determinants of response vs. resistance of treatment-…
Active NIH Awards
- 3R01CA276156-04S1: Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies (2026)
- 5R01CA276156-04: Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies (2026)
- 3R01CA276156-03S1: Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies (2025)
- 5R01CA276156-03: Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies (2025)
- 5R01CA276156-02: Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies (2024)
Explore 700+ US Biology Labs on FindBioLabs.com